{"composite_breakdown_label":"","computation_units":"Million Icelandic Kr\u00f3na (MISK)","copyright":"","data_footnote":"","data_non_statistical":false,"data_notice_class":"","data_notice_heading":"","data_notice_text":"","data_show_map":false,"data_start_values":[],"embedded_feature_footer":"","embedded_feature_html":"","embedded_feature_tab_title":"","embedded_feature_title":"","embedded_feature_url":"","expected_disaggregations":[],"graph_annotations":[],"graph_limits":[],"graph_stacked_disaggregation":"","graph_title":"Total net official development assistance to medical research and basic health sectors","graph_titles":[],"graph_type":"line","indicator_name":"Total net official development assistance to medical research and basic health sectors","indicator_number":"3.b.2","national_geographical_coverage":"Iceland","page_content":"\nMedical research is not an emphasis in Icelandic development assistance and in 2019 no official development assistance was allocated to the medical reserach. However, in 2019 Iceland allocated 144.5 MISK in development assistance to projects associated with SDG 3.\n","permalink":"/3-b-2/","precision":[],"reporting_status":"complete","sort":"","standalone":false,"tags":[],"goal_meta_link":"https://unstats.un.org/sdgs/metadata/files/Metadata-03-0B-02.pdf","goal_meta_link_text":"United Nations Sustainable Development Goals Metadata (PDF 210 KB)","indicator":"3.b.2","indicator_definition":"Total ODA flows to developing countries quantify the public effort that donors provide to developing countries for medical research and basic health.","indicator_sort_order":"03-bb-02","layout":"indicator","published":true,"sdg_goal":"3","target":"Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","target_id":"3.b","un_custodian_agency":"Organisation for Economic Co-operation (OECD)","un_designated_tier":"1","national_indicator_available":"Total net official development assistance to medical research and basic health sectors","data_keywords":"HIV, s\u00fdkingar","comments_limitations":"Data follows the UN specification for this indicator. This indicator has been identified in collaboration with topic experts.","source_active_1":true,"source_organisation_1":"Ministry for Foreign Affairs","source_periodicity_1":"Annual","source_earliest_available_1":2019,"source_geographical_coverage_1":"Iceland","source_url_1":null,"source_url_text_1":null,"source_release_date_1":null,"source_next_release_1":null,"source_statistical_classification_1":"Official Statistics","source_contact_1":"utn@utn.is","national_metadata_updated_date":"2023-08-09","national_data_updated_date":"2023-08-09","SDG_GOAL__GLOBAL":"<p>Goal 3: Ensure healthy lives and promote well-being for all at all ages</p>","SDG_TARGET__GLOBAL":"<p>Target 3.b: Support the research and development of vaccines and medicines for the communicable and non&#x2011;communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all</p>","SDG_INDICATOR__GLOBAL":"<p>Indicator 3.b.2: Total net official development assistance to medical research and basic health sectors</p>","SDG_SERIES_DESCR__GLOBAL":"<p>DC_TOF_HLTHL - Total official development assistance to medical research and basic heath sectors, gross disbursement, by recipient countries [3.b.2]</p>\n<p>DC_TOF_HLTHNT - Total official development assistance to medical research and basic heath sectors, net disbursement, by recipient countries [3.b.2]</p>","META_LAST_UPDATE__GLOBAL":"2025-04-23","SDG_RELATED_INDICATORS__GLOBAL":"<p>Other ODA indicators </p>","SDG_CUSTODIAN_AGENCIES__GLOBAL":"<p>Organisation for Economic Co-operation and Development (OECD) </p>","CONTACT_ORGANISATION__GLOBAL":"<p>Organisation for Economic Co-operation and Development (OECD) </p>","STAT_CONC_DEF__GLOBAL":"<p><strong>Definition:</strong> </p>\n<p>Gross disbursements of total official development assistance (ODA) from all donors to medical research and basic health sectors. </p>\n<p>Recipient country: &#x201C;Developing countries&#x201D; refer to countries which are eligible to receive ODA as listed in the OECD/Development Assistance Committee (DAC) List of ODA Recipients (see<a href=\"https://www.oecd.org/en/topics/oda-eligibility-and-conditions/dac-list-of-oda-recipients.html\">https://www.oecd.org/en/topics/oda-eligibility-and-conditions/dac-list-of-oda-recipients.html</a>). Hence this indicator is only applicable to recipient countries that are on the List.</p>\n<p> </p>\n<p><strong>Concepts:</strong> </p>\n<p>ODA: Since 2018, the OECD/DAC defines ODA as those flows to countries and territories on the DAC List of ODA Recipients and to multilateral development institutions which are: </p>\n<ol>\n  <li>provided by official agencies, including state and local governments, or by their executive agencies; and</li>\n  <li>each transaction of which:<ol>\n      <li>is administered with the promotion of the economic development and welfare of developing countries as its main objective; and<ul>\n          <li>is concessional in character. In DAC statistics, this implies a grant element of at least 45 per cent in the case of bilateral loans to the official sector of LDCs and other LICs<em> (calculated at a rate of discount of 9 per cent)</em>.</li>\n          <li>15 per cent in the case of bilateral loans to the official sector of LMICs <em>(calculated at a rate of discount of 7 per cent)</em>.</li>\n          <li>10 per cent in the case of bilateral loans to the official sector of UMICs <em>(calculated at a rate of discount of 6 per cent)</em>.</li>\n          <li>10 per cent in the case of loans to multilateral institutions <em>(calculated at a rate of discount of 5 per cent for global institutions and multilateral development banks, and 6 per cent for other organisations, including sub-regional organisations)</em> .</li>\n        </ul>\n      </li>\n    </ol>\n  </li>\n</ol>\n<p>Loans whose terms are not consistent with the IMF Debt Limits Policy and/or the World Bank&#x2019;s Non-Concessional Borrowing Policy are not reportable as ODA.</p>\n<p>See: <a href=\"https://www.oecd.org/en/topics/sub-issues/oda-eligibility-and-conditions/official-development-assistance--definition-and-coverage.html\">https://www.oecd.org/en/topics/sub-issues/oda-eligibility-and-conditions/official-development-assistance--definition-and-coverage.html</a>.</p>\n<p>Prior to 2018, ODA was defined as above but the grant element of an activity needed to be at least 25 per cent (calculated at a rate of discount of 10 per cent). </p>\n<p> </p>\n<p> </p>\n<p>Medical research and basic health sectors are as defined by the DAC. Medical research refers to CreditorReporting System (CRS) sector code 12182 and basic health covers all codes in the 122 series (see here DAC/CRS codes: https://webfs.oecd.org/oda/DataCollection/Resources/) </p>","SOURCE_TYPE__GLOBAL":"<p>The OECD/DAC has been collecting data on official and private resource flows from 1960 at an aggregate level and 1973 at an activity level through the Creditor Reporting System (CRS data are considered complete from 1995 for commitments at an activity level and 2002 for disbursements). </p>\n<p> </p>\n<p>The data are reported by donors according to the same standards and methodologies (see here: <a href=\"https://one.oecd.org/document/DCD/DAC(2024)40/FINAL/en/pdf\">https://one.oecd.org/document/DCD/DAC(2024)40/FINAL/en/pdf</a>). </p>\n<p> </p>\n<p>Data are reported on an annual calendar year basis by statistical reporters in national administrations (aid agencies, Ministries of Foreign Affairs or Finance, etc. </p>","COLL_METHOD__GLOBAL":"<p>A statistical reporter is responsible for the collection of DAC statistics in each providing country/agency. This reporter is usually located in the national aid agency, Ministry of Foreign Affairs or Finance etc. </p>","FREQ_COLL__GLOBAL":"<p>Data are published on an annual basis in December for flows in the previous year. </p>","REL_CAL_POLICY__GLOBAL":"<p>Annual data release in December. </p>","DATA_SOURCE__GLOBAL":"<p>Data are reported on an annual calendar year basis by statistical reporters in national administrations (aid agencies, Ministries of Foreign Affairs or Finance, etc. </p>","COMPILING_ORG__GLOBAL":"<p>OECD </p>","RATIONALE__GLOBAL":"<p>Total ODA flows to developing countries on the DAC List of ODA Recipients quantify the public effort that donors provide to developing countries for medical research and basic health. </p>","REC_USE_LIM__GLOBAL":"<p>Data in the Creditor Reporting System are available from 1973. However, the data coverage is considered complete from 1995 for commitments at an activity level and 2002 for disbursements. </p>","DATA_COMP__GLOBAL":"<p>From a recipient country&#x2019;s perspective: The sum of ODA flows from all donors (i.e. DAC donors, multilateral organisations and other bilateral providers of development cooperation) to developing countries on the DAC List of ODA Recipients for medical research and basic health.</p>","IMPUTATION__GLOBAL":"<ul>\n  <li><strong>At country level </strong></li>\n</ul>\n<p> </p>\n<p>Due to high quality of reporting, no estimates are produced for missing data. </p>\n<p> </p>\n<ul>\n  <li><strong>At regional and global levels </strong></li>\n</ul>\n<p> </p>\n<p>Not applicable. </p>","REG_AGG__GLOBAL":"<p>Global and regional figures are based on the sum of ODA flows to medical research and basic health. </p>","COVERAGE__GLOBAL":"<p><strong>Data availability:</strong></p>\n<p>This indicator is only applicable on a recipient basis where recipient countries comprise all developing countries eligible for ODA on the DAC List of ODA Recipients. </p>\n<p>Countries that are not eligible for ODA are excluded from this indicator.</p>\n<p><strong>Time series:</strong></p>\n<p>Data available since 1973 on an annual (calendar) basis </p>\n<p><strong>Disaggregation:</strong></p>\n<p>This indicator can be disaggregatedby donor, recipient country on the DAC List of ODA Recipients, by type of finance, by type of aid, by health sub-sector, etc. </p>","COMPARABILITY__GLOBAL":"<p><strong>Sources of discrepancies:</strong></p>\n<p>DAC statistics are standardized on a calendar year basis for all donors and may differ from fiscal year data available in budget documents for some countries. </p>","OTHER_DOC__GLOBAL":"<p><strong>URL:</strong> </p>\n<p> </p>\n<p>https://www.oecd.org/en/topics/oda-standards.html </p>\n<p><strong>References:</strong> </p>\n<p> </p>\n<p>See all links here: https://www.oecd.org/en/topics/oda-standards.html</p>","target_number":"3.b","goal_number":"3"}